Mode
Text Size
Log in / Sign up

Meta-analysis identifies new genetic loci linked to acute myeloid leukemia risk in 4710 casesNew Genetic Map Reveals Hidden Leukemia Risk Factors

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Meta-analysis identifies new genetic loci at 2p23.3, 1q23.3, 2q33.3, and 2p21 linked to AML risk.

This meta-analysis examined the association between common genetic variants and the risk of acute myeloid leukemia (AML). The study included 4710 AML cases and 12,938 controls, focusing on variants at 1q23.3, 2p23.3, 2q33.3, and 2p21. The analysis aimed to determine if these genetic markers influence AML risk, survival, or clonal hematopoiesis.

The authors identified four new genome-wide significant risk loci. A pan-AML risk locus was found at 2p23.3 (rs4665765) with a P value of 1.35 × 10^-8. Additional loci were identified at 1q23.3 (rs12078864) for AML with deletions of chromosome 5 and/or 7 (P = 7.0 × 10^-10), at 2q33.3 (rs12988876) for cytogenetically complex AML (P = 3.28 × 10^-8), and at 2p21 (rs79918355) for cytogenetically complex AML (P = 1.60 × 10^-9).

Patient survival was significantly associated with the genetic variants (P = 6.09 × 10^-3). The study also assessed the risk of clonal hematopoiesis (CH) and CH of indeterminate potential, though specific effect sizes for these outcomes were not reported in the provided data. No adverse events or tolerability data were available.

The authors did not report funding, conflicts of interest, or specific limitations. Given the observational nature of the genetic data, causal language is avoided. The clinical relevance for routine practice is not explicitly detailed in the source text.

Body

Imagine knowing your risk before symptoms ever appear. For many families, leukemia feels like a surprise attack with no warning signs. Now, scientists have found new clues hidden inside our DNA.

Why understanding genetics matters

Acute myeloid leukemia is a serious blood cancer. It grows fast and needs urgent care. Doctors often struggle to predict who will get it.

This disease affects people of all ages. It is one of the most common blood cancers in adults. Yet, the reasons behind it remain complex.

The surprising shift in science

We used to think only family history mattered. But this study shows common DNA changes play a bigger role. It changes how we look at risk.

Previously, we could only identify rare genetic errors. Now, we see how common variations add up. This offers a clearer picture of the disease.

How DNA acts like a blueprint

Think of your genes as an instruction manual for your body. Sometimes, small typos in that manual change how cells grow. These new spots are like warning labels on the page.

They do not cause the disease alone. Instead, they might make the cells more sensitive to other triggers. It is like a weak spot in a wall.

The team combined data from six different studies. They looked at nearly 17,000 people in total. This gave them a much clearer picture than before.

They compared people with the disease to healthy controls. This method helps find patterns that are easy to miss. It is like finding a needle in a haystack.

What they found in the data

They identified four specific locations on the DNA strand. One location affects the overall risk of the disease. Another location is linked to how well patients survive.

The study also found risks for specific subgroups. For example, some markers appear in patients with chromosome changes. This helps doctors understand different types of the illness.

This doesn’t mean this treatment is available yet.

Expert perspective on the findings

Experts say this helps build a better map of the disease. Future tests might include these markers for better planning. But we need more work first.

This research connects to a condition called clonal hematopoiesis. It shows how blood cells change before cancer starts. This link is vital for prevention strategies.

This is still early research for doctors. It is not a test you can order at a pharmacy. Talk to your doctor if you have concerns.

You should not worry about these findings alone. They are part of a larger puzzle. Your personal risk depends on many factors.

Why we still have questions

This research looked at groups of people, not individuals. It does not tell us exactly why the disease starts. We still need to learn more about the environment.

Genetics is only one piece of the story. Lifestyle and other factors also play a major role. We cannot blame DNA for everything.

The road ahead for patients

Researchers will keep testing these findings in new groups. Approval for new tests takes years of careful review. Stay tuned for updates from trusted medical sources.

Scientists are working to turn these clues into tools. Eventually, this could help doctors choose better treatments. But patience is key for real progress.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Acute myeloid leukemia (AML) is a complex hematologic malignancy with multiple disease subgroups defined by somatic mutations and heterogeneous outcomes. Although genome-wide association studies (GWAS) have identified a small number of common genetic variants influencing AML risk, the heritable component of this disease outside of familial susceptibility remains largely undefined. Here, we perform a meta-analysis of 4 published GWAS plus 2 new GWAS, totaling 4710 AML cases and 12 938 controls. We identify a new genome-wide significant risk locus for pan-AML at 2p23.3 (rs4665765; P = 1.35 × 10-8; EFR3B, POMC, DNMT3A, and DNAJC27), which also significantly associates with patient survival (P = 6.09 × 10-3). Our analysis also identifies 3 new genome-wide significant risk loci for disease subgroups, including AML with deletions of chromosome 5 and/or 7 at 1q23.3 (rs12078864; P = 7.0 × 10-10; DUSP23) and cytogenetically complex AML at 2q33.3 (rs12988876; P = 3.28 × 10-8; PARD3B) and 2p21 (rs79918355; P = 1.60 × 10-9; EPCAM). We also investigated loci previously associated with the risk of clonal hematopoiesis (CH) or CH of indeterminate potential and identified several variants associated with the risk of AML. Our results further inform on AML etiology and demonstrate the existence of disease subgroup specific risk loci.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.